Pesquisar
Edwards Lifesciences Corp
EWAdicionar à lista de desejos
87.360USD
+0.680+0.78%
Fechamento 06/18, 16:00（ET）Cotações atrasadas em 15 min
50.30BValor de mercado
46.39P/L TTM
Mais detalhes de Edwards Lifesciences Corp Empresa
Edwards Lifesciences Corporation is the global structural heart company. The Company partners with clinicians and researchers and invests in research and development to improve care for those impacted by structural heart disease. Its product categories include Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical Structural Heart. It provides transcatheter heart valve replacement technologies designed for the minimally-invasive replacement of aortic heart valves. TAVR category includes the Edwards SAPIEN 3, the Edwards SAPIEN 3 Ultra and the Edwards SAPIEN 3 Ultra RESILIA systems. TMTT category includes the PASCAL Precision transcatheter repair system, EVOQUE tricuspid valve replacement system and Cardioband tricuspid valve reconstruction system. Its INSPIRIS RESILIA aortic valve, offers RESILIA tissue and VFit technology. It is managed in various geographical regions, such as United States, Europe, Japan and Rest of World.
Informações de Edwards Lifesciences Corp
Código da empresaEW
Nome da EmpresaEdwards Lifesciences Corp
Data de listagemMar 27, 2000
CEOZovighian (Bernard J)
Número de funcionários15800
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 27
EndereçoOne Edwards Way
CidadeIRVINE
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal92614
Telefone19492502500
Sitehttps://www.edwards.com
Código da empresaEW
Data de listagemMar 27, 2000
CEOZovighian (Bernard J)
Executivos da empresa Edwards Lifesciences Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Mr. Donald E. Bobo, Jr.
Mr. Donald E. Bobo, Jr.
Corporate Vice President - Strategy and Corporate Development
Corporate Vice President - Strategy and Corporate Development
--
--
Mr. Nicholas J. (Nick) Valeriani
Mr. Nicholas J. (Nick) Valeriani
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Kieran T. Gallahue
Mr. Kieran T. Gallahue
Independent Director
Independent Director
--
--
Ms. Leslie S. Heisz
Ms. Leslie S. Heisz
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Scott B. Ullem
Mr. Scott B. Ullem
Chief Financial Officer, Corporate Vice President
Chief Financial Officer, Corporate Vice President
284.40K
+2.48%
Mr. Steven R. (Steve) Loranger
Mr. Steven R. (Steve) Loranger
Independent Director
Independent Director
79.69K
+5.41%
Mr. Daniel J. Lippis
Mr. Daniel J. Lippis
Corporate Vice President - Transcatheter Aortic Valve Replacement
Corporate Vice President - Transcatheter Aortic Valve Replacement
39.67K
+16.33%
Mr. Bernard J. Zovighian
Mr. Bernard J. Zovighian
Chief Executive Officer, Director
Chief Executive Officer, Director
30.12K
+59.32%
Mr. Daveen Chopra
Mr. Daveen Chopra
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
Corporate Vice President - Transcatheter Mitral and Tricuspid Therapies
22.62K
+53.60%
Dr. David T. Feinberg, M.D.
Dr. David T. Feinberg, M.D.
Independent Director
Independent Director
5.56K
+58.48%
Perguntas frequentes
Quem são os cinco principais acionistas de Edwards Lifesciences Corp?
Os cinco principais acionistas de Edwards Lifesciences Corp são: Mr. Scott B. Ullem
Quantas instituições possuem ações da Edwards Lifesciences Corp (EW)?
Em 2026Q1, 2620 instituições possuíam ações da Edwards Lifesciences Corp, com valor de mercado aproximado de 539.60M, representando 93.71% do total de ações. Em comparação com 2025Q4, a participação institucional aumentou em -12944884.00.
Qual é a maior fonte de receita da Edwards Lifesciences Corp?
Em 2026Q1, o segmento de negócios Transcatheter Aortic Valve Replacement gerou a maior receita para Edwards Lifesciences Corp, totalizando 4.49B e representando 73.96% da receita total.
